This will suppress the dimerization of HER2 with other HER family members to finally block the downstream signaling pathways and inhibit HER2‐positive breast cancer growth (Figure 6).[9e] The nanoMIP specifically inhibited HER2 phosphorylation and proliferation of HER2‐positive tumor cells in a dose‐dependent fashion. This evidence concerns the gene ERBB2 and breast carcinoma.